{"paper_id":"77df8480-d8f3-4d17-87f3-fee0b2e39127","body_text":"Abstract\nA noninvasive diagnostic test for endometriosis is needed to shorten the current diagnostic delay of 8–11 years. The goal of this study was to discover new biomarkers for endometriosis using an antibody array approach. A total of 103 plasma samples from patients with laparoscopically confirmed presence (n = 68) or absence (n = 35) of endometriosis were selected. Samples were pooled according to disease status, cycle phase, disease stage, and phenotype. Pooled samples were screened for possible biomarkers using the L-series 1000 and Quantibody 660 arrays from RayBiotech. Technical verification of ten markers was done using a custom-made multiplex immunoassay identifying ten proteins (10-plex) and later by single ELISA. Due to the limited reproducibility of the L-series 1000 immunoassay, the biomarker screening was performed using the Quantibody 660, a sandwich-based multiplex immunoassay, which showed that 280 proteins were upregulated, and 29 proteins downregulated in the endometriosis pool versus the control pool. In order to assess the reproducibility of these results, ten preselected proteins were analyzed using a custom 10-plex. Four proteins (CD48, DNAM-1, IL-31, and XIAP) were confirmed to be differentially expressed when comparing the endometriosis and control pool. However, only IL-31 showed a univariate statistical difference between endometriosis and control groups in individual samples that were part of the initial pools. In conclusion, discovery and verification of potential markers proved challenging using multiplex immunoassay methods, mainly due to issues with reproducibility. Only IL-31 showed potential as possible biomarker for endometriosis.\nSimilar content being viewed by others\nReferences\nGiudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447):1789–99.\nASRM. Revised ASRM classification for endometriosis: 1996. Fertil Steril. 1997;67:820.\nNisolle M, Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril. 1997;68(4):585–96.\nAghajanova L, Giudice LC. Molecular evidence for differences in endometrium in severe versus mild endometriosis. Reprod Sci. 2011;18(3):229–51.\nDunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, de Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–12.\nKennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20(10):2698–704.\nHusby GK, Haugen RS, Moen MH. Diagnostic delay in women with pain and endometriosis. Acta Obstet Gynecol Scand. 2003;82(7):649–53.\nMay KE, Conduit-Hulbert SA, Villar J, Kirtley S, Kennedy SH, Becker CM. Peripheral biomarkers of endometriosis: a systematic review. Hum Reprod Update. 2010;16(6):651–74.\nNisenblat V, Bossuyt PM, Shaikh R, et al. Blood biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016;5:CD012179.\nRogers PA, Adamson GD, Al-Jefout M, et al. Research priorities for endometriosis. Reprod Sci. 2017;24(2):202–26.\nO DF, Flores I, Waelkens E, D'Hooghe T. Noninvasive diagnosis of endometriosis: Review of current peripheral blood and endometrial biomarkers. Best Pract Res Clin Obstet Gynaecol. 2018.\nTemplin MF, Stoll D, Schwenk JM, Potz O, Kramer S, Joos TO. Protein microarrays: promising tools for proteomic research. Proteomics. 2003;3(11):2155–66.\nLeng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci. 2008;63(8):879–84.\nHuang RP, Burkholder B, Jones VS, et al. Cytokine antibody arrays in biomarker discovery and validation. Curr Proteomics. 2012;9(1):55–70.\nKingsmore SF. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov. 2006;5(4):310–20.\nO DF, El Aalamat Y, Waelkens E, De Moor B, D'Hooghe T, Fassbender A. Multiplex immunoassays in endometriosis: An array of possibilities. Front Biosci (Landmark Ed). 2017;22:479–92.\nFassbender A, Vodolazkaia A, Saunders P, Lebovic D, Waelkens E, de Moor B, et al. Biomarkers of endometriosis. Fertil Steril. 2013;99(4):1135–45.\nKendziorski C, Irizarry RA, Chen KS, Haag JD, Gould MN. On the utility of pooling biological samples in microarray experiments. Proc Natl Acad Sci U S A. 2005;102(12):4252–7.\nHou Z, Sun L, Gao L, Liao L, Mao Y, Liu J. Cytokine array analysis of peritoneal fluid between women with endometriosis of different stages and those without endometriosis. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2009;14(8):604–18.\nD'Hooghe TM, Mihalyi AM, Simsa P, Kyama CK, Peeraer K, de Loecker P, et al. Why we need a noninvasive diagnostic test for minimal to mild endometriosis with a high sensitivity. Gynecol Obstet Investig. 2006;62(3):136–8.\nDiz AP, Truebano M, Skibinski DO. The consequences of sample pooling in proteomics: an empirical study. Electrophoresis. 2009;30(17):2967–75.\nHeegaard NH, Ostergaard O, Bahl JM, et al. Important options available--from start to finish--for translating proteomics results to clinical chemistry. Proteomics Clin Appl. 2015;9(1–2):235–52.\nJiang H, Zhang L, Yu Y, Liu M, Jin X, Zhang P, et al. A pilot study of angiogenin in heart failure with preserved ejection fraction: a novel potential biomarker for diagnosis and prognosis? J Cell Mol Med. 2014;18(11):2189–97.\nBrowne AS, Yu J, Huang RP, Francisco AM, Sidell N, Taylor RN. Proteomic identification of neurotrophins in the eutopic endometrium of women with endometriosis. Fertil Steril. 2012;98(3):713–9.\nTing L, Cowley MJ, Hoon SL, Guilhaus M, Raftery MJ, Cavicchioli R. Normalization and statistical analysis of quantitative proteomics data generated by metabolic labeling. Mol Cell Proteomics. 2009;8(10):2227–42.\nGusnanto A, Calza S, Pawitan Y. Identification of differentially expressed genes and false discovery rate in microarray studies. Curr Opin Lipidol. 2007;18(2):187–93.\nZhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008;19(5–6):347–56.\nZeng X, Zhang Z, Gao QQ, et al. Clinical significance of serum Interleukin-31 and Interleukin-33 levels in patients of endometrial Cancer: a case control study. Dis Markers. 2016;2016:9262919.\nHuang R, Jiang W, Yang J, Mao YQ, Zhang Y, Yang W, et al. A biotin label-based antibody array for high-content profiling of protein expression. Cancer Genomics Proteomics. 2010;7(3):129–41.\nToh HC, Wang WW, Chia WK, Kvistborg P, Sun L, Teo K, et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal Cancer patients. Clin Cancer Res. 2009;15(24):7726–36.\nTorres C, Linares A, Alejandre MJ, et al. Prognosis relevance of serum cytokines in pancreatic Cancer. Biomed Res Int. 2015;2015:518284.\nWang WW, Ang SF, Kumar R, Heah C, Utama A, Tania NP, et al. Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. PLoS One. 2013;8(7):e68904.\nVargas-Inchaustegui DA, Hogg AE, Tulliano G, Llanos-Cuentas A, Arevalo J, Endsley JJ, et al. CXCL10 production by human monocytes in response to Leishmania braziliensis infection. Infect Immun. 2010;78(1):301–8.\nMahlknecht P, Stemberger S, Sprenger F, Rainer J, Hametner E, Kirchmair R, et al. An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. Proteome Sci. 2012;10(1):71.\nBjorkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One. 2012;7(1):e29868.\nChen Z, Dodig-Crnkovic T, Schwenk JM, Tao SC. Current applications of antibody microarrays. Clin Proteomics. 2018;15:7.\nArellano-Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, et al. Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis. 2008;14(8):705–12.\nTighe PJ, Ryder RR, Todd I, Fairclough LC. ELISA in the multiplex era: potentials and pitfalls. Proteomics Clin Appl. 2015;9(3–4):406–22.\nHaab BB. Methods and applications of antibody microarrays in cancer research. Proteomics. 2003;3(11):2116–22.\nWellhausen R, Seitz H. Facing current quantification challenges in protein microarrays. J Biomed Biotechnol. 2012;2012:831347.\nHu WG, Thompson HG, Alvi AZ, Nagata LP, Suresh MR, Fulton RE. Development of immunofiltration assay by light addressable potentiometric sensor with genetically biotinylated recombinant antibody for rapid identification of Venezuelan equine encephalitis virus. J Immunol Methods. 2004;289(1–2):27–35.\nVoskuil J. How difficult is the validation of clinical biomarkers? F1000Res. 2015;4:101.\nBielohuby M, Bidlingmaier M, Schwahn U. Control of (pre)-analytical aspects in immunoassay measurements of metabolic hormones in rodents. Endocr Connect. 2018;7(4):R147–59.\nVos SJ, Visser PJ, Verhey F, Aalten P, Knol D, Ramakers I, et al. Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. PLoS One. 2014;9(6):e100784.\nAcknowledgments\nWe thank Ana Arraztio (TebuBio) and the staff of RayBiotech, in particular Jarad Wilson (RayBiotech), for excellent technical support; M. Welkenhuysen for acquiring patient consent; G. Vriens, C. Tomassetti, C. Meuleman and K. Peeraer for their contributions to the sample collection; all patients who have given consent for sample collection.\nFunding\nGrant support: Funding of this research was obtained from the Research Foundation-Flanders (FWO, application number 11X5515N).\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nConflict of Interest\nProf Dr. Thomas D’Hooghe is Vice President and Head Global Medical Affairs Fertility, Research and Development, Merck KGaA, Darmstadt, Germany. He is also a Professor in Reproductive Medicine and Biology at the Department of Development and Regeneration, Group Biomedical Sciences, KU Leuven (University of Leuven), Belgium, and an Adjunct Professor at the Department of Obstetrics and Gynecology in the University of Yale, New Haven, USA. Neither his corporate role nor his academic roles represent a conflict of interest with respect to the work done by him for this study.\nAdditional information\nAmelie Fassbender Thomas D’Hooghe should be regarded as joint last authors\nElectronic Supplementary Material\nESM1 (download JPG )\n(JPG 113 kb)\nESM2\n(DTD 43 kb)\nRights and permissions\nAbout this article\nCite this article\nO, D., Waelkens, E., Vanhie, A. et al. The Use of Antibody Arrays in the Discovery of New Plasma Biomarkers for Endometriosis. Reprod. Sci. 27, 751–762 (2020). https://doi.org/10.1007/s43032-019-00081-w\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s43032-019-00081-w","source_license":"CC0","license_restricted":false}